The estimated Net Worth of Christopher J Margolin is at least $1.57 Milión dollars as of 31 March 2005. Christopher Margolin owns over 53,700 units of XOMA Royalty stock worth over $1,510,231 and over the last 21 years Christopher sold XOMA stock worth over $55,311.
Christopher has made over 2 trades of the XOMA Royalty stock since 2004, according to the Form 4 filled with the SEC. Most recently Christopher sold 53,700 units of XOMA stock worth $55,311 on 31 March 2005.
The largest trade Christopher's ever made was exercising 75,000 units of XOMA Royalty stock on 12 January 2004 worth over $187,500. On average, Christopher trades about 5,850 units every 20 days since 2003. As of 31 March 2005 Christopher still owns at least 55,687 units of XOMA Royalty stock.
You can see the complete history of Christopher Margolin stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY, CA, 94710.
Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
XOMA Royalty executives and other stock owners filed with the SEC include: